Assay Report
Methods · Standard Curves · QC · Results
Specialized Enzyme-Linked ImmunoSpot (ELISpot) and FluoroSpot testing services to evaluate cellular immune responses directed against AAV capsids (AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAV-Rh10, and engineered variants) and therapeutic transgene products in human, non-human primate (NHP), and rodent peripheral blood mononuclear cells (PBMCs) and splenocytes.
By quantifying antigen-specific IFN-γ and IL-2 spot-forming units (SFU) down to 1 in 1,000,000 cells following peptide library stimulation, our platform supports pre-existing immunity screening, vector design optimization, and non-clinical gene therapy safety evaluation.
Universal experimental design dimensions ensuring sound biological comparison and analytical specificity.
| Planning Dimension | Core Parameters Defined Collaboratively | Impact on Data Integrity & Interpretation |
|---|---|---|
| Peptide Library Design | Synthetic 15-mer peptides overlapping by 11 amino acids spanning entire VP1/VP2/VP3 capsid and transgene sequences | Ensures unbiased representation of all possible linear CD4+ and CD8+ T-cell epitopes across diverse MHC alleles. |
| Control Arm Configuration | Negative control (DMSO/media <5 SFU/well), Positive control (phytohemagglutinin [PHA] / anti-CD3 >500 SFU/well), Recall control (CEFX viral pool) | Validates baseline PBMC viability, confirms non-specific background thresholds, and verifies immunocompetence. |
| PBMC Pre-Culture & Resting | 18–24 hour resting phase at 37°C in Benzonase-supplemented medium prior to antigen exposure | Minimizes post-thaw background noise and eliminates false-positive stress-induced spot formation. |
| Dual-Target Co-Secretion | Combining IFN-γ (cytolytic effector activation) with IL-2 (proliferative central memory) in FluoroSpot format | Differentiates active cytotoxic destruction of transduced cells from resting immune memory reserves. |
| Cohort Sampling Kinetics | Pre-dose baseline vs. acute post-treatment (Day 7–14) and longitudinal follow-up (Month 1–12+) | Maps the complete temporal curve of capsid clearance kinetics versus persistent anti-transgene expansion. |
Validated ELISpot and FluoroSpot testing configurations across natural AAV serotypes, engineered capsids, and transgenes.
| Vector / Analyte Target | Serotype & Epitope Scope | Primary Detection Endpoint | Preclinical Research & Application Focus |
|---|---|---|---|
| AAV Capsid Immunogenicity Portfolio | AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAV-Rh10 | IFN-γ & IL-2 Spot-Forming Units (SFU) | Pre-existing memory screening, seroprevalence mapping, and capsid re-engineering candidate evaluation. |
| Transgene Product Immunogenicity | Factor VIII, Factor IX, Micro-Dystrophin, GAA, IDUA | Transgene-specific T-cell frequencies | Differentiating anti-transgene neoantigen responses from anti-capsid reactivity in null-mutation animal models. |
| Engineered & Novel Synthetic Capsids | Directed-evolution variants (AAV-PHP.eB, Anc80, capsids) | Deconvoluted capsid peptide pools | Benchmarking immune evasion and stealth properties of novel next-generation synthetic capsids. |
| Gene-Editing Nucleases (Cas9 / Cas12) | SpCas9, SaCas9, Cas12a, Base/Prime Editors | Nuclease-specific CD4+/CD8+ SFU | Assessing pre-existing human PBMC immunity against bacterial CRISPR-Cas nuclease payloads. |
| NHP & Small Animal Translational Panels | Cynomolgus, Rhesus, Mouse, Rat PBMCs & Splenocytes | Species-specific qualified ELISpot reagents | Non-human primate dose-escalation studies and longitudinal transgenic rodent safety models. |
Evaluating immunological readout, target resolution, and sample requirements across gene therapy bioanalytical platforms.
| Technical Dimension | AAV PBMC ELISpot (Our Service) | Neutralizing Antibody (NAb) Assay | Flow Cytometry ICS | Soluble Cytokine Multiplex |
|---|---|---|---|---|
| Immune Branch Measured | Cellular Immunity (T Cells) | Humoral Immunity (Antibodies) | Cellular Immunity (T Cells) | Innate / Systemic Cytokines |
| Target Antigen Resolution | Single-cell functional secretion | Transduction inhibition titer | Intracellular cytokine staining | Total accumulated serum concentration |
| Sensitivity Threshold | 1 in 100,000 to 1 in 1,000,000 | Transduction IC50 titer | ~1 in 1,000 (Low sensitivity) | 0.010 – 5.0 pg/mL |
| Biological Material Required | Viable PBMCs or Splenocytes | Serum or Plasma | Viable PBMCs | Serum, Plasma, or Supernatant |
| Capsid vs Transgene Separation | Distinct mapped peptide pools | Transduction assay dependent | Co-staining dependent | No (Systemic sum) |
| Throughput & Automation | High (Automated 96-well imaging) | Moderate (Luciferase/GFP flow) | Moderate (Flow acquisition) | High (96/384-well automated) |
Standardized operating procedures, automated spot deconvolution, and rigorous quality gating.
Synthetic 15-mer peptide libraries synthesized at >90% purity, validated by LC-MS, and formulated with minimal DMSO to prevent non-specific cellular toxicity.
Advanced multi-channel optical algorithms eliminate spot-overlap artifacts, distinguish true biological secretion from cellular debris, and quantify Relative Spot Volumes.
Positive responder calls require test well SFU >3× negative background and delta >50 SFU/10^6 cells, ensuring robust statistical reproducibility.
Controlled thawing of cryopreserved human/NHP PBMCs in warm media with Benzonase; 18-hour resting at 37°C.
Seeding 200,000 viable PBMCs per well into PVDF plates pre-coated with anti-IFN-γ or anti-IL-2 capture antibodies.
Adding capsid peptide pools (VP1/2/3), transgene peptide pools, positive controls (PHA/CEFX), or DMSO negative controls.
Washing cells and incubating with biotinylated or fluorophore-conjugated detection antibodies followed by substrate development.
Automated imaging on Mabtech readers, spot counting, background subtraction, and delivery of normalized SFU/10^6 cell reports.
Standardized PBMC isolation and cryopreservation protocols ensuring high post-thaw viability and reliable T-cell responsiveness.
| Pre-Analytical Parameter | Why It Matters for AAV Cellular Immunogenicity | Intake Specification & Recommendation |
|---|---|---|
| PBMC Isolation Timing | Granulocyte contamination from delayed processing causes non-specific background and blunted T-cell responses. | Isolate PBMCs via density gradient centrifugation (Ficoll-Paque) within 8 hours of blood draw. |
| Cryopreservation Medium | Suboptimal freezing protocols damage fragile memory T-cell subsets, leading to false-negative immunogenicity readouts. | Resuspend in pre-chilled freezing medium (90% FBS + 10% DMSO or CryoStor CS10); freeze at -1°C/min. |
| Post-Thaw Cell Viability | Dying cells release DNA and non-specific proteases, increasing background noise and suppressing antigen-specific activation. | Cell viability must exceed 80%; include a 1–2 hour recovery resting phase at 37°C prior to plating. |
| Input Cell Quantity | Multi-pool capsid and transgene matrix testing requires sufficient cell aliquots across replicate wells. | Provide minimum 10–15 × 10^6 cryopreserved viable cells per donor/timepoint. |
| Peptide Solubilization | Excess DMSO in working wells causes non-specific cellular toxicity and false-negative spot inhibition. | Reconstitute peptide pools in sterile DMSO/PBS; ensure final in-well DMSO concentration is strictly <0.25% v/v. |
Applying AAV ELISpot testing across pre-existing immunity screening, transgene safety, and vector optimization.
Screen healthy human donor PBMCs to evaluate baseline T-cell reactivity against AAV2, AAV5, AAV8, and AAV9 serotypes.
Detect de novo T-cell responses against replacement proteins (Factor VIII/IX, micro-dystrophin, enzymes) in null-mutation disease models.
Quantify pre-existing or treatment-emergent CD4+/CD8+ T-cell responses against bacterial Cas9/Cas12 nucleases in gene-editing pipelines.
Benchmark the cellular immune profile of engineered, capsid-shuffled, or chemically modified AAV vectors against wild-type capsids.
Monitor longitudinal cellular immune responses in NHP cohorts to determine safe dosing windows and immunosuppression regimens.
Generate comprehensive preclinical immunogenicity data packages supporting non-clinical exploratory study dossiers.
Standardized bioanalytical documentation, annotated spot images, and senior immunologist consultation.
Key peer-reviewed publications establishing AAV capsid T-cell epitope mapping and clinical trial monitoring.
Study Design Takeaway: Landmark discovery demonstrating that cytotoxic CD8+ T cells directed against AAV capsids eliminate transduced hepatocytes and cause transaminitis in clinical trials.
Study Design Takeaway: Details overlapping peptide library ELISpot methodologies to map immunodominant capsid epitopes across distinct AAV serotypes.
Study Design Takeaway: Reviews cellular immune responses directed against foreign transgene products (e.g. micro-dystrophin) and outlines pre-analytical ELISpot monitoring protocols.
Study Design Takeaway: Utilizes ELISpot to demonstrate widespread pre-existing human T-cell immunity against SpCas9 and SaCas9, establishing essential safety screening parameters.
Addressing common project planning, cell handling, and assay selection inquiries.
Neutralizing antibodies only measure the humoral blockade of vector cell entry. In contrast, ELISpot measures cytotoxic and helper T-cell activation directed against intracellularly processed capsid peptides and transgene products, which can destroy transduced cells even in the absence of high NAb titers.
Yes. By using separate, non-overlapping peptide libraries—one spanning the AAV capsid protein (VP1/VP2/VP3) and another spanning the therapeutic transgene sequence—ELISpot independently quantifies anti-vector versus anti-transgene T-cell responses from the same PBMC sample.
We utilize 15-mer synthetic peptides overlapping by 11 amino acids spanning the entire capsid and transgene sequences. Peptides are organized into sub-pools (e.g., Pool A, Pool B, Pool C) or two-dimensional matrix pools to conserve cell numbers and enable rapid epitope deconvolution.
Standard protocols require 200,000 viable PBMCs per well. For a typical AAV screening panel (unstimulated background, positive control, 2–4 capsid pools, and 1–2 transgene pools in duplicate), we recommend providing 10–15 × 10^6 cryopreserved viable PBMCs.
A response is typically classified as positive if the mean spot count in antigen-stimulated wells exceeds 3 times the negative control (DMSO/media background) and yields a net delta of >50 SFU per 10^6 PBMCs (or empirical cut-offs established during study validation).
No. All bioanalysis services provided by Creative Proteomics are strictly for Research Use Only (RUO). They are intended for preclinical vector discovery, non-human primate studies, animal disease models, and translational research cohorts, and are not intended for clinical diagnostic or patient management procedures.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×